Unfortunately, only a handful of autoantibodies has been described so far, and their discovery and validation for clinical purposes is a slow, laborious and expensive task.
We think there are plenty of targets to get excited about in the field of immunokinase modulation, many with strong preclinical rationale and compelling human genetic linkages despite lacking clinical-stage pharmacologic validation.
It appears to be superior to standard antibody-based quality-control tests currently used for that purpose, but such scientific advances will need to undergo extensive validation studies before they can be considered a reliable predictor of effects in vivo and eliminate the need for clinical data.